作者
Robert W. Myers,Hong-Ping Guan,Juliann Ehrhart,Aleksandr Petrov,S. Prahalada,Effie Tozzo,Xiao-Dong Yang,Marc M. Kurtz,Maria E. Trujillo,Dinko González Trotter,Danqing Feng,Shiyao Xu,George J. Eiermann,Marie A. Holahan,Daniel Rubins,Stacey Conarello,Xiaoda Niu,Sandra C. Souza,Corin Miller,Jinqi Liu,Ku Lu,Feng Wen,Ying Li,Ronald E. Painter,James A. Milligan,Huaibing He,Franklin Liu,Aimie M. Ogawa,Douglas Wisniewski,Rory J. Rohm,Liyang Wang,Michelle Bunzel,Ying Qian,Wei Zhu,Hongwu Wang,Bindu Bennet,Lisa LaFranco-Scheuch,Guillermo Estrada Fernández,Cai Li,Michael Klimas,Gaochao Zhou,Margaret van Heek,Tesfaye Biftu,Ann E. Weber,David E. Kelley,Nancy A. Thornberry,Mark D. Erion,Daniel M. Kemp,Iyassu K. Sebhat
摘要
Hitting a dozen enzymes with one drug The adenosine monophosphate-activated protein kinase (AMPK) controls cellular energy status. AMPK is activated when energy levels fall. This stimulates adenosine triphosphate (ATP)-generating pathways that promote glucose uptake and inhibits ATP-consuming pathways associated with glucose synthesis. In principle, these effects would be beneficial in metabolic diseases, including diabetes. Pharmacological activation of AMPK has been challenging, however, because in mammals, the enzyme exists as 12 distinct complexes. Myers et al. describe an orally available compound (MK-8722) that activates all 12 complexes (see the Perspective by Hardie). In animal models, MK-8722 ameliorated diabetes, but it also caused enlargement of the heart. MK-8722 may be a useful tool compound for laboratory research on AMPK function. Science , this issue p. 507 ; see also p. 455